Dai ichi Life Insurance Company Ltd Takes $497,000 Position in Avantor, Inc. (NYSE:AVTR)

Dai ichi Life Insurance Company Ltd acquired a new stake in Avantor, Inc. (NYSE:AVTR) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 19,222 shares of the company’s stock, valued at approximately $497,000.

Several other hedge funds also recently added to or reduced their stakes in the business. Versant Capital Management Inc lifted its stake in shares of Avantor by 2,003.6% in the 2nd quarter. Versant Capital Management Inc now owns 1,157 shares of the company’s stock valued at $25,000 after purchasing an additional 1,102 shares during the last quarter. Blue Trust Inc. raised its holdings in Avantor by 1,830.3% in the 2nd quarter. Blue Trust Inc. now owns 1,467 shares of the company’s stock valued at $31,000 after buying an additional 1,391 shares during the period. UMB Bank n.a. acquired a new position in Avantor in the third quarter valued at about $49,000. Nisa Investment Advisors LLC boosted its stake in Avantor by 69.6% during the third quarter. Nisa Investment Advisors LLC now owns 2,035 shares of the company’s stock worth $53,000 after buying an additional 835 shares during the period. Finally, GAMMA Investing LLC increased its position in shares of Avantor by 89.9% during the third quarter. GAMMA Investing LLC now owns 2,715 shares of the company’s stock valued at $70,000 after acquiring an additional 1,285 shares during the last quarter. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have recently commented on AVTR. Wells Fargo & Company decreased their price objective on shares of Avantor from $30.00 to $28.00 and set an “overweight” rating on the stock in a report on Monday, October 28th. Robert W. Baird lowered their price target on Avantor from $27.00 to $26.00 and set an “outperform” rating for the company in a research report on Monday, October 28th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $34.00 price objective on shares of Avantor in a research note on Thursday, September 26th. Barclays decreased their target price on Avantor from $28.00 to $25.00 and set an “overweight” rating on the stock in a research note on Friday, October 25th. Finally, UBS Group dropped their target price on Avantor from $30.00 to $29.00 and set a “buy” rating for the company in a research report on Tuesday, October 8th. Three analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat.com, Avantor currently has a consensus rating of “Moderate Buy” and an average price target of $27.57.

Avantor Stock Up 0.1 %

Shares of Avantor stock opened at $21.04 on Friday. Avantor, Inc. has a 52-week low of $19.59 and a 52-week high of $28.00. The company has a 50 day moving average of $23.40 and a 200 day moving average of $23.76. The company has a quick ratio of 1.06, a current ratio of 1.54 and a debt-to-equity ratio of 0.84. The company has a market capitalization of $14.32 billion, a P/E ratio of 45.74, a P/E/G ratio of 2.56 and a beta of 1.35.

Insider Transactions at Avantor

In related news, CAO Steven W. Eck sold 3,525 shares of the business’s stock in a transaction that occurred on Thursday, September 5th. The stock was sold at an average price of $25.06, for a total transaction of $88,336.50. Following the completion of the sale, the chief accounting officer now owns 29,544 shares in the company, valued at $740,372.64. The trade was a 10.66 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 1.30% of the company’s stock.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.